Vækstfonden backs Nanovi with €600,000

The fresh capital, which is the company's second round of seed funding, will be used to achieve a proof-of-concept for its first product.

The company estimates the sales potential of its product to reach €100m, while the new technology taps into a wider market worth in excess of €10bn.

Previous funding
Seed Capital provided seed funding for Nanovi earlier this year.

Company
Based in Copenhagen, Nanovi develops products based on advanced biomaterials for use in the treatment of cancer. The company's first product, BioXmark, is an injectable tissue liquid marker used to improve accuracy in the radiation treatment of patients with cancer. The product will be available for commercial use in Europe around 2015.

People
Jesper Roested is an investment director at Vækstfonden. Jón Ingi Benediktsson is an investment manager at Seed Capital. Morten Albrechtsen is the CEO and co-founder of Nanovi.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Early-stage
• Healthcare
• Technology
• Now researching
• Denmark